文献速递儿童神经与发育行为儿童血液肿瘤与免疫

儿童抗癫痫药物相关白细胞减少常见且临床影响轻微

Leukopenia in Children on Antiseizure Medication is Common and Has Minor Clinical Impact.
PubMed 文献 · J Pediatr · 2025-04-17

该回顾性队列研究纳入198例接受抗癫痫药物(ASM)治疗的儿童,发现49%出现至少一次白细胞减少,其中88%为轻度,仅4%需调整ASM,无危及生命事件。结论认为白细胞减少比既往描述更常见,但多无症状且无并发症,轻度时可能无需停药或调整。

要点

  • 接受ASM治疗的儿童中49%出现白细胞减少,多数为轻度。
  • 仅4%的白细胞减少事件需调整ASM,无危及生命病例。
  • 轻度白细胞减少时可能无需停用或调整ASM。

核心结论

  • 儿童ASM相关白细胞减少比既往描述更常见,但多无症状且无并发症,轻度时可能无需停药或调整。

研究设计与样本

  • 回顾性队列研究,纳入Astrid Lindgren儿童医院最近198例接受ASM治疗的18岁以下儿童,比较发生与未发生白细胞减少者。

主要发现

  • 仅9次(4%)白细胞减少事件采取了ASM更换或减量等临床措施,7次(3%)出现白细胞减少症状。
  • 发生白细胞减少的儿童更常合并其他血细胞减少(62% vs 18%;P < .001)。
  • 发生白细胞减少的风险因素包括其他器官系统功能障碍、更长治疗时长、ASM联合治疗及年龄略大(平均11 vs 9岁,P = .03)。

关键数值与推荐

  • 轻度白细胞减少定义为低于正常下限至3.0×10^9 cells/L。
  • 几乎所有ASM治疗中均可见白细胞减少,仅少数组间有显著差异,老一代与新型ASM之间白细胞减少发生率无差异。

临床怎么用

  • 对接受ASM治疗的儿童应认识白细胞减少常见但多轻微,轻度无症状时可能无需停用或调整ASM。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the prevalence, risk factors, and impact of leukopenia among children treated with antiseizure medication (ASM) in a real-world setting. STUDY DESIGN: The most recent 198 pediatric (<18 years) patients treated with ASMs at Astrid Lindgren Children's Hospital were included in a retrospective cohort study. Clinical variables were collected from electronic medical records. Patients who did and did not develop leukopenia were compared. RESULTS: Ninety-seven (49%) patients developed at least 1 episode of leukopenia. Most episodes (180 [88%]) were mild (ie, lower normal limit - 3.0 × 109 cells/L) and no patient developed life-threatening leukopenia or died. Clinical actions (ie, ASM switch or tapering) were taken in only 9 (4%) episodes of leukopenia. The clinical impact was leukopenia symptoms in 7 (3%) episodes, and other blood cell cytopenias more frequently (62% vs 18%; P < .001) compared with children without leukopenia. The risk factors for developing leukopenia were dysfunction in other organ systems (eg, endocrinologic disorders, heart disease, or kidney disease), longer treatment duration, ASM combination treatments, and slightly older age (mean 11 vs 9 years, P = .03). Leukopenia was seen in treatments with almost all ASMs (ie, substances) with only a few significant differences between the groups. There was no difference in leukopenia incidence between older vs newer ASMs. CONCLUSIONS: Leukopenia is a far more common side-effect of ASMs than earlier described. However, this leukopenia is mostly asymptomatic and without complications. If mild leukopenia occurs, ASM discontinuation or adjustment may not be necessary.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Pettersson H, Alani T, Rydén I, et al. Leukopenia in Children on Antiseizure Medication is Common and Has Minor Clinical Impact. J Pediatr. 2025. PMID: 40252960. doi:10.1016/j.jpeds.2025.114593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。